Skip to main content
Terug
Watch Compare

Senti Biosciences, Inc.

Datakwaliteit: 100%
SNTI
Nasdaq Manufacturing Chemicals
€ 0,87
▲ € 0,00 (0,37%)
Marktkapitalisatie: 26,82 M
Prijs
€ 0,86
Marktkapitalisatie
26,82 M
Dagbereik
52-Weeksbereik
Volume
Openen —
50D / 200D Gem.
50D / 200D Gem.

Quick Summary

Belangrijkste Punten

Negative free cash flow of -43,64 M
Capital intensive — 890,91% of revenue goes to capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-374,93%
Onder sectorgemiddelde (-53,41%)
ROIC-109,54%
Net Margin-279263,64%
Op. Margin-312631,82%

Veiligheid

Debt / Equity
N/A
Current Ratio1,51
Interest CoverageN/A

Waardering

PE (TTM)
-0,44
Boven sectorgemiddelde (-1,48)
P/B Ratio3,30
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,4 -1,5
P/B 3,3 1,6
ROE % -374,9 -53,4
Net Margin % -279263,6 -41,5
Rev Growth 5Y % 1,8
D/E 0,3

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) -90,73%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 22.000,0 Net Income (TTM) -61,44 M
ROE -374,93% ROA -101,36%
Gross Margin N/A Operating Margin -312631,82%
Net Margin -279263,64% Free Cash Flow (TTM) -43,64 M
ROIC -109,54% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,51
Interest Coverage N/A Asset Turnover 0,00
Working Capital 6,13 M Tangible Book Value 8,12 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,44 Forward P/E N/A
P/B Ratio 3,30 P/S Ratio 1218,88
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -162,74%
Market Cap 26,82 M Enterprise Value 14,57 M
Per Share
EPS (Diluted TTM) -2,73 Revenue / Share 0,00
FCF / Share -1,40 OCF / Share -1,39
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 890,91% FCF Conversion 71,03%
SBC-Adj. FCF -48,59 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Revenue 22.000,0 0,0 2,56 M 4,29 M
Net Income -61,44 M -52,79 M -71,06 M -3,86 M -58,21 M
EPS (Diluted) -2,73 -12,03 -1,60 -2,23
Gross Profit
Operating Income -68,78 M -61,04 M -92,73 M -3,87 M -70,63 M
EBITDA
R&D Expenses 37,59 M 34,36 M 32,15 M 34,07 M
SG&A Expenses
D&A
Interest Expense
Income Tax 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Total Assets 51,22 M 97,84 M 119,48 M 231,46 M 180,79 M
Total Liabilities 45,63 M 47,09 M 52,57 M 10,33 M 53,53 M
Shareholders' Equity 5,59 M 25,65 M 66,91 M -8,88 M 127,26 M
Total Debt
Cash & Equivalents 16,42 M 48,28 M 35,93 M 889.323,0 57,62 M
Current Assets 23,27 M 58,96 M 71,20 M 1,30 M 102,58 M
Current Liabilities 13,97 M 13,15 M 12,67 M 3,28 M 18,05 M